INDIANAPOLIS, June 13, 2020 /PRNewswire/ -- New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide ...
"The incidence of type 2 diabetes among youth and adolescents is on the rise, particularly among minority populations, and the disease can be even more progressive and difficult to treat than in ...
Trulicity (dulaglutide), a once-weekly subcutaneous injection, has been approved by the U.S. Food and Drug Administration to improve glycemic control in adults with type 2 diabetes along with diet and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback